3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
8
Radiotherapy
7
Cisplatin
6
pembrolizumab
4
Fluorouracil
4
Surgical Procedures, Operative
3
Radiation
3
Oxaliplatin
3
Levoleucovorin
3
Leucovorin
3
Esophagectomy
3
Drug Therapy
3
Carboplatin
3
lenvatinib
2
durvalumab
2
Taxes
2
TP protocol
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Neoadjuvant Therapy
2
Irinotecan
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tislelizumab
1
palbociclib
1
osimertinib
1
obinutuzumab
1
nedaplatin
1
naptumomab estafenatox
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Esophageal Squamous Cell Carcinoma
×
Saline Solution
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled